LeMaitre Vascular (LMAT) insider details option exercises and trust transfer

Rhea-AI Filing Summary

LeMaitre Vascular Inc. reported insider activity by its chairman and CEO, who is also a director, involving multiple transactions in company common stock on 12/11/2025 and 12/12/2025. The activity included exercises of stock options at exercise prices of $37.29, $48.6, $47.19 and $54.65, as well as releases of dividend equivalent rights that resulted in share acquisitions at $0 per share.

The filing notes that several dispositions reflect shares withheld by the issuer to cover tax obligations tied to vesting restricted stock units and performance stock units, treated as exempt sales under Rule 16b-3(e). It also records a transfer of 12,100 shares from the reporting person’s direct holdings to the LeMaitre Irrevocable Life Insurance Trust of 2025. After these transactions, the reporting person directly owns 1,682,304 common shares, and 33,400 shares are held indirectly by the trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeMaitre George W

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		M		54(1)	A	$0(1)	1,670,159	D
Common Stock	12/11/2025		F		652(2)	D	$83.36	1,669,507	D
Common Stock	12/12/2025		M		5,155(3)	A	$37.29	1,674,662	D
Common Stock	12/12/2025		M		7,733(3)	A	$48.6	1,682,395	D
Common Stock	12/12/2025		M		7,075(3)	A	$47.19	1,689,470	D
Common Stock	12/12/2025		M		6,182(3)	A	$54.65	1,695,652	D
Common Stock	12/12/2025		G		12,100	D	$0	1,683,552	D
Common Stock	12/12/2025		A		12,100	A	$0	33,400	I	LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025(4)
Common Stock	12/12/2025		M		39(1)	A	$0(1)	1,683,591	D
Common Stock	12/12/2025		F		663(5)	D	$84	1,682,928	D
Common Stock	12/12/2025		M		39(1)	A	$0(1)	1,682,967	D
Common Stock	12/12/2025		F		663(6)	D	$84	1,682,304	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(7)	12/11/2025		M			54(7)	(7)	(7)	Common Stock	54	$0	0(8)	D
Stock Option (Right to Buy)	$37.29	12/12/2025		M			5,155	12/02/2020(9)	12/02/2027	Common Stock	5,155	$0	0	D
Stock Option (Right to Buy)	$48.6	12/12/2025		M			7,733	12/11/2021(9)	12/11/2028	Common Stock	7,733	$0	0	D
Stock Option (Right to Buy)	$47.19	12/12/2025		M			7,075	12/12/2022(10)	12/12/2029	Common Stock	7,075	$0	9,194	D
Stock Option (Right to Buy)	$54.65	12/12/2025		M			6,182	12/08/2023(10)	12/08/2030	Common Stock	6,182	$0	14,191	D
Dividend Equivalent Rights	(11)	12/12/2025		M			39(11)	(11)	(11)	Common Stock	39	$0	41.9311	D
Dividend Equivalent Rights	(12)	12/12/2025		M			39(12)	(12)	(12)	Common Stock	39	$0	41.2224	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/11/2021. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

3. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

4. These shares are held by an irrevocable trust for the benefit of Reporting Person's child(ren). The Reporting Person disclaims ownership of such securities except to the extent of his pecuniary interest therein, if any, and the reporting herein of such securities shall not be construed as an admission of beneficial ownership thereof for the purposes of Section 16 or for any other purpose.

5. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

6. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of performance stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

7. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/11/2021. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

8. Fractional shares released (if any) on each vesting date were settled in cash, resulting in a final balance of zero.

9. This option is fully vested and exercisable.

10. This option is exercisable and vests over a four-year period at a rate of 25% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining three years.

11. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

12. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did LeMaitre Vascular (LMAT) report in this filing?

The filing shows the chairman and CEO executed multiple transactions in LeMaitre Vascular common stock on 12/11/2025 and 12/12/2025, including stock option exercises, releases of dividend equivalent rights, share transfers, and share withholding for taxes on equity awards.

How many LeMaitre Vascular (LMAT) shares does the reporting person own after these transactions?

After the reported transactions, the reporting person directly owns 1,682,304 shares of LeMaitre Vascular common stock, and 33,400 shares are held indirectly by the LeMaitre Irrevocable Life Insurance Trust of 2025.

What stock options did the LeMaitre Vascular insider exercise in this Form 4?

The insider exercised stock options covering shares of LeMaitre Vascular common stock at exercise prices of $37.29, $48.6, $47.19, and $54.65, as reflected in the non-derivative and derivative tables.

Why were some LeMaitre Vascular (LMAT) shares withheld in this insider filing?

Certain dispositions represent shares withheld by the issuer to satisfy tax withholding obligations from the vesting of restricted stock units and performance stock units, which the filing describes as exempt sales under Rule 16b-3(e).

What is the LeMaitre Irrevocable Life Insurance Trust of 2025 mentioned in the filing?

The filing reports that 12,100 shares of LeMaitre Vascular common stock were transferred from the reporting person’s direct holdings to the LeMaitre Irrevocable Life Insurance Trust of 2025, which holds shares for the benefit of the reporting person’s child or children.

How are dividend equivalent rights treated in this LeMaitre Vascular Form 4?

The filing explains that certain dividend equivalent rights were released in connection with vesting restricted stock unit and performance stock unit awards, with each right being the economic equivalent of one share of LeMaitre Vascular common stock.